TNFR2 is also highly specific to immunosuppressive cells aside from aberrant expression on the surface of cancer cells, meaning immunotherapies may have less undesirable side effects when compared to treatments with checkpoint inhibitors targeting proteins, such as PD-1 [81]. Here, PDCD1 is linked to cancer.